Kura Oncology, Inc.
DE ˙ DB ˙ US50127T1097
7,56 € ↑0,24 (3,28%)
2026-06-05
DEL PRIS
SecurityDE:KUR / Kura Oncology, Inc.
InstitutionRhumbline Advisers
Latest Disclosed Ownership104,815 shares
Latest Disclosed Value $ 852,138
Rhumbline Advisers reports 0.35% increase in ownership of KUR / Kura Oncology, Inc.

On May 12, 2026 - Rhumbline Advisers filed a 13F-HR form disclosing ownership of 104,815 shares of Kura Oncology, Inc. (DE:KUR) valued at $697,020 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 104,447 shares of Kura Oncology, Inc.. This represents a change in shares of 0.35% during the quarter. The current value of the position is $792,401 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F KURA ONCOLOGY COM 50127T109 104,815 368 0.35 852 -21.47 0.0007
2026-02-13 2025-12-31 13F KURA ONCOLOGY COM 50127T109 104,447 -15,488 -12.91 1,085 2.26 0.0009
2025-11-06 2025-09-30 13F KURA ONCOLOGY COM 50127T109 119,935 1,039 0.87 1,061 54.66 0.0009
2025-08-12 2025-06-30 13F KURA ONCOLOGY COM 50127T109 118,896 13,690 13.01 686 -1.15 0.0006
2025-05-29 2025-03-31 13F/A-1 KURA ONCOLOGY COM 50127T109 105,206 5,215 5.22 694 -20.23 0.0006
2025-04-08 2025-03-31 13F KURA ONCOLOGY COM 50127T109 105,206 5,215 694 0.0006
2025-05-29 2024-12-31 13F/A-1 KURA ONCOLOGY COM 50127T109 99,991 1,923 1.96 871 -54.59 0.0008
2025-01-30 2024-12-31 13F KURA ONCOLOGY COM 50127T109 99,991 1,923 871 0.0008
2024-11-12 2024-09-30 13F KURA ONCOLOGY COM 50127T109 98,068 -6,108 -5.86 1,916 -10.63 0.0017
2024-08-01 2024-06-30 13F KURA ONCOLOGY COM 50127T109 104,176 -9,432 -8.30 2,145 -11.51 0.0020
2024-05-09 2024-03-31 13F KURA ONCOLOGY COM 50127T109 113,608 1,545 1.38 2,423 50.40 0.0023
2024-02-08 2023-12-31 13F KURA ONCOLOGY COM 50127T109 112,063 1,187 1.07 1,611 59.35 0.0017
2023-11-09 2023-09-30 13F KURA ONCOLOGY COM 50127T109 110,876 5,260 4.98 1,011 -9.49 0.0012
2023-08-08 2023-06-30 13F KURA ONCOLOGY COM 50127T109 105,616 1,613 1.55 1,117 111,600.00 0.0013
2023-05-11 2023-03-31 13F KURA ONCOLOGY COM 50127T109 104,003 3,300 3.28 1 -99.92 0.0016
2023-02-14 2022-12-31 13F KURA ONCOLOGY COM 50127T109 100,703 2,379 2.42 1,250 -6.92 0.0017
2022-11-10 2022-09-30 13F KURA ONCOLOGY COM 50127T109 98,324 6,733 7.35 1,343 -20.01 0.0020
2022-08-11 2022-06-30 13F KURA ONCOLOGY COM 50127T109 91,591 8,106 9.71 1,679 25.11 0.0025
2022-05-12 2022-03-31 13F KURA ONCOLOGY COM 50127T109 83,485 -7,131 -7.87 1,342 5.75 0.0017
2022-02-10 2021-12-31 13F KURA ONCOLOGY COM 50127T109 90,616 -1,124 -1.23 1,269 -26.14 0.0016
2021-11-12 2021-09-30 13F KURA ONCOLOGY COM 50127T109 91,740 2,900 3.26 1,718 -7.24 0.0023
2021-08-05 2021-06-30 13F KURA ONCOLOGY COM 50127T109 88,840 21,248 31.44 1,852 -3.09 0.0024
2021-05-06 2021-03-31 13F KURA ONCOLOGY COM 50127T109 67,592 -2,498 -3.56 1,911 -16.51 0.0026
2021-02-10 2020-12-31 13F KURA ONCOLOGY COM 50127T109 70,090 7,091 11.26 2,289 18.60 0.0032
2020-11-12 2020-09-30 13F KURA ONCOLOGY COM 50127T109 62,999 -8,360 -11.72 1,930 65.95 0.0030
2020-08-13 2020-06-30 13F KURA ONCOLOGY COM 50127T109 71,359 28,878 67.98 1,163 174.94 0.0019
2020-05-06 2020-03-31 13F KURA ONCOLOGY COM 50127T109 42,481 281 0.67 423 -27.07 0.0009
2020-02-05 2019-12-31 13F KURA ONCOLOGY COM 50127T109 42,200 1,739 4.30 580 -5.54 0.0010
2019-10-23 2019-09-30 13F KURA ONCOLOGY COM 50127T109 40,461 2,649 7.01 614 -17.58 0.0011
2019-08-14 2019-06-30 13F KURA ONCOLOGY COM 50127T109 37,812 1,503 4.14 745 23.75 0.0014
2019-05-01 2019-03-31 13F KURA ONCOLOGY COM 50127T109 36,309 -809 -2.18 602 15.55 0.0012
2019-01-31 2018-12-31 13F KURA ONCOLOGY COM 50127T109 37,118 13,781 59.05 521 27.70 0.0011
2018-11-07 2018-09-30 13F KURA ONCOLOGY COM 50127T109 23,337 -310 -1.31 408 -5.12 0.0008
2018-08-06 2018-06-30 13F KURA ONCOLOGY COM 50127T109 23,647 5,552 30.68 430 26.84 0.0009
2018-05-02 2018-03-31 13F KURA ONCOLOGY COM 50127T109 18,095 4,160 29.85 339 59.15 0.0007
2018-02-09 2017-12-31 13F KURA ONCOLOGY COM 50127T109 13,935 -910 -6.13 213 -4.05 0.0004
2017-11-06 2017-09-30 13F KURA ONCOLOGY COM 50127T109 14,845 746 5.29 222 69.47 0.0005
2017-08-02 2017-06-30 13F KURA ONCOLOGY COM 50127T109 14,099 14,099 131 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.